Evotec AG and the Jain Foundation, Inc. have further extended their collaboration to include the screening of compound libraries in multiple assay formats to support Jain’s discovery efforts for dysferlinopathies, an inherited skeletal muscular dystrophy diseases. Financial terms were not disclosed.   Dr. Mario Polywka, chief operating officer of Evotec, said, “We are delighted to continue our relationship with the Jain Foundation and to be a part of this important step in dysferlin ...